Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
NCT05995353Phase 3Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Dec 2023
- Primary completion
- Apr 2029
- Modality
- Monoclonal Antibodies
- Countries
- 21
01
Overview
A Phase 3 trial of risankizumab in Crohn's disease, sponsored by AbbVie Inc.. Started Dec 2023; status: recruiting.
02
Drugs
risankizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT05995353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05995353.